The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BCYC | -69.94% | -58.5% | -16.13% | -34% |
| S&P | +14.5% | +93.32% | +14.09% | +137% |
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
The company said it is working with the FDA to structure a phase 2/3 trial for its bladder cancer therapy.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.95M | -68.5% |
| Gross Profit | $1.24M | -84.0% |
| Gross Margin | 41.92% | -40.6% |
| Market Cap | $480.96M | -44.3% |
| Market Cap / Employee | $1.58M | 0.0% |
| Employees | 305 | 7.4% |
| Net Income | -$79.89M | -100.4% |
| EBITDA | -$98.33M | -87.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $721.45M | -25.0% |
| Accounts Receivable | $0.14M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.55M | -83.2% |
| Short Term Debt | $5.43M | -80.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -25.78% | -3.9% |
| Return On Invested Capital | -33.05% | 2.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$74.33M | -64.7% |
| Operating Free Cash Flow | -$73.82M | -65.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.88 | 1.16 | 0.74 | 0.65 | -73.20% |
| Price to Sales | 42.23 | 27.41 | 22.80 | 24.88 | -6.41% |
| Price to Tangible Book Value | 1.88 | 1.16 | 0.74 | 0.65 | -73.20% |
| Enterprise Value to EBITDA | -9.65 | -1.26 | 2.52 | 2.36 | -192.67% |
| Return on Equity | -26.8% | -29.1% | -37.1% | -31.6% | 4.33% |
| Total Debt | $11.09M | $9.49M | $9.12M | $7.99M | -81.31% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
